Tacrolimus capsules + Cyclophosphamide injections + Prednisone
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Nephritis
Conditions
Lupus Nephritis
Trial Timeline
Mar 10, 2015 → Sep 10, 2018
NCT ID
NCT02457221About Tacrolimus capsules + Cyclophosphamide injections + Prednisone
Tacrolimus capsules + Cyclophosphamide injections + Prednisone is a phase 3 stage product being developed by Astellas Pharma for Lupus Nephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02457221. Target conditions include Lupus Nephritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02457221 | Phase 3 | Completed |
Competing Products
20 competing products in Lupus Nephritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisone | Astellas Pharma | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| E6742 | Eisai | Phase 1/2 | 41 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3471851 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3471851 + Placebo | Eli Lilly | Phase 2 | 52 |
| Itolizumab [Bmab 600] | Biocon | Phase 1 | 33 |